Panbela Provides Business Update and Reports Q2 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Panbela Therapeutics, Inc. (PBLA) Misses Q2 EPS by $1.25
August 15, 2022 4:56 PM EDTPanbela Therapeutics, Inc. (NASDAQ: PBLA) reported Q2 EPS of ($1.51), $1.25 worse than the analyst estimate of ($0.26).
For earnings history and earnings-related data on Panbela Therapeutics, Inc. (PBLA) click here.
... More